Abstract

Rationale: The real-world REDES study reinforced mepolizumab effectiveness and safety in Severe Eosinophilic Asthma (SEA) patients in Spain. This post hoc analysis assessed if FEV₁ had an influence on clinical improvement with mepolizumab.

Methods: REDES was an observational study of mepolizumab therapy outcomes in SEA patients in Spain. We report here the outcomes at 12 months of treatment stratified by FEV₁ ranges: <50%, 50-70% and >70% (percentages of predicted value).

Results: Age, BMI, atopic sensitization, and comorbidities were similar in the three groups. Exacerbations were reduced by 75-87%, OCS reduction and interruption varied differently between groups, without a clear trend. The only difference between groups was the FEV₁ change, greater in patients with lower baseline FEV₁. (Table)

Conclusions: Our results show the influence of baseline FEV₁ on lung function improvement with an anti-IL5 in clinical practice but that other patients’ features and clinical outcomes with mepolizumab are independent of baseline lung function status.

Funding: GSK (GSK ID 213172)